Name: sample extraction and simultaneous chromatographic quantitation of doxorubicin and mitomycin c following drug combination delivery in nanoparticles to tumor-bearing mice
Uploaded: 2017-10-05T13:00:00
Description: Watch this Scientific Journal Video about Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-b

Forfatterne parlamentsarbejdet udstyr tilskud fra naturvidenskab og teknisk forskning (NSERC) Council of Canada til HPLC, driftstilskud fra det canadiske Institut for sundhed Research (CIHR) og canadiske bryst kræft forskning (CBCR) Alliance til X.Y. Wu, og University of Toronto legat til R.X. Zhang og T. Zhang.

alle dyreforsøg blev godkendt af de dyr Care Udvalget af University Health Network på Ontario Cancer Institute og gennemføres i overensstemmelse med den canadiske Rådet om dyrs pleje retningslinjer.
 1. biologiske prøveforberedelse <ol><li>indsamle fuldblod, vigtige organer, og bryst tumor på forud fastsatte tidspunkter efter intravenøs (IV) indgift af lægemiddel-holdige formuleringer (f.eks., DMPLN, liposomal DOX) <ol><li>indsprøjtes et bryst tumor-bæren...

Sammenlignet med andre kromatografiske metoder, der muliggør påvisning af en enkelt drug arter ad gangen, er denne HPLC protokol købedygtig samtidig kvantificere tre narkotika forbindelser (DOX, MMC og DOXol) i den samme biologiske matrix uden at skulle ændre den mobile fase. Denne forberedelse og analyse metode har været anvendt med succes til at bestemme farmakokinetik og bio-distribution af to nanopartikel-baseret drug delivery systems (dvs. liposomal DOX og DMPLN)22. Da pegyl...

Kemoterapi er en primær behandling modalitet for mange kræftformer, men det er ofte forbundet med alvorlige bivirkninger og begrænset effektivitet på grund af lægemiddelresistens og andre faktorer1,2,3. For at forbedre resultatet af kemoterapi er narkotika kombination regimer blevet anvendt i klinikken er baseret på overvejelser som ikke-overlappende toksiciteter, forskellige mekanismer af narkotika handling, og ikke-cross drug resistance4,5 , 6. i kliniske forsøg, en bedre tumor responsrate var ofte observeret ved hjælp af samtidig administreret medicin kombinationer i forhold til et regime af sekventielle drug delivery7,8. Dog, på grund af sub-optimale bio-distribution af gratis narkotika former, samtidig indsprøjtning af flere stoffer kan forårsage fremtrædende normale væv toksicitet, der opvejer de terapeutiske effekt9,10,11. Nanocarrier-baseret drug delivery har vist sig at ændre farmakokinetik og bio-distribution af indkapslede narkotika, forbedre tumor-målrettet ophobning12,13,14. Som gennemgået i vores seneste artikler, har nanopartikler Co fyldt med synergistiske drug kombinationer vist evne til at afhjælpe problemer med fri narkotika kombinationer, på grund af deres kontrollerede tidsmæssige og rumlige Co levering af flere stoffer til tumor væv, aktivering synergistiske narkotika effekter mod kræft celler4,15,16. Som et resultat, har overlegen terapeutiske virkning og lav toksicitet påvist i både prækliniske og kliniske undersøgelser4,17,18.
Vores tidligere in vitro- undersøgelser fundet at kombinationen af to anticancermedicin, doxorubicin (DOX) og mitomycin C (MMC), produceret en synergistisk effekt mod flere bryst kræft celler linjer og derudover Co lastning DOX og MMC inden for polymer-lipid hybrid nanopartikler (DMPLN) overvandt forskellige multiresistent tilknyttede efflux pumper (fx P-glykoprotein og bryst kræft resistente protein)19,20,21. In vivo, aktiveret DMPLN rumlige-temporale Co levering af DOX og MMC til tumor websteder og øget biotilgængelighed af narkotika i kræftceller, som angivet af moderation af dannelsen af DOX metabolit doxorubicinol (DOXol)22. Som et resultat forøget af DMPLN tumor celle apoptose, tumor væksthæmning og langvarig vært overlevelse i forhold til fri kombination af DOX og MMC eller en liposomal DOX formulering22,23,24, 25.
Analysere den faktiske mængde narkotika Co leveret af en nanocarrier er kritisk for at designe effektiv nanopartikel formuleringer. Mange metoder har været udviklet til at analysere niveauet plasma af enkelt DOX eller MMC doser ved hjælp af højtryksvæskekromatografi (HPLC) alene eller i kombination med massespektrometri (MS)26,27,28 , 29 , 30 , 31 , 32 , 33 , 34. men disse metoder er ofte tidskrævende og upraktisk for kombinationsbehandling som et stort antal biologiske prøver skal udarbejdes særskilt analyse af flere stoffer (undertiden herunder narkotika metabolitter). Den stærke plasmaproteinbinding af DOX og MMC har røde blodlegemer en stor evne til at binde og koncentrere mange anticancermedicin35,36. Således kan plasma analyse for DOX eller MMC obfuscate faktiske blod stof koncentrationer. Den nuværende arbejde (figur 1) beskriver en enkel og robust flere narkotika analysemetode med omvendt fase HPLC samtidig ekstrakt og kvantificere DOX, MMC og DOX metabolit doxorubicinol (DOXol) fra fuldblod og forskellige væv ( fx tumorer). Det har været anvendt med succes til at bestemme farmakokinetik og bio-distribution af DOX og MMC og dannelsen af DOXol efter medicinafgivelse via gratis løsninger eller nanopartikel former (dvs.DMPLN og liposomal DOX) i en orthotopically implanteret murine bryst-tumor musemodel efter intravenøs (IV) injektion22.

<table style="border-collapse:collapse;width:635pt" width="846">
	<colgroup>
		<col style="width:188pt" width="250" />
		<col style="width:122pt" width="162" />
		<col style="width:89pt" width="119" />
		<col style="width:236pt" width="315" />
	</colgroup>
	<tbody>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">Doxorubicin&#160;</td>
			<td class="xl20" style="width:122pt" width="162">Polymed Theraeutics</td>
			<td class="xl20" style="width:89pt" width="119">111023</td>
			<td class="xl20" style="width:236pt" width="315">Anticancer drug</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">Mitomycin C</td>
			<td class="xl20" style="width:122pt" width="162">Polymed Theraeutics</td>
			<td class="xl20" style="width:89pt" width="119">060814</td>
			<td class="xl20" style="width:236pt" width="315">Anticancer drug</td>
		</tr>
		<tr height="42" style="height:31.5pt">
			<td class="xl20" height="42" style="width:188pt;height:31.5pt" width="250">Doxorubicinol (DOXol)</td>
			<td class="xl20" style="width:122pt" width="162">Toronto Research Chemicals</td>
			<td class="xl20" style="width:89pt" width="119">D558020</td>
			<td class="xl21">Metabolite of DOX</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">4-Methylumbelliferone sodium salt&#160;</td>
			<td class="xl20" style="width:122pt" width="162">Sigma-Aldrich</td>
			<td class="xl20" style="width:89pt" width="119">M1508</td>
			<td class="xl21">Internal standard</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">Myristic Acid</td>
			<td class="xl20" style="width:122pt" width="162">Sigma-Aldrich</td>
			<td class="xl20" style="width:89pt" width="119">544-63-8&#160;&#160;</td>
			<td class="xl21">Materials for poly-lipid hybrid nanoparticles</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">Polyoxyethylene (100) Stearate</td>
			<td class="xl20" style="width:122pt" width="162">Spectrum</td>
			<td class="xl20" style="width:89pt" width="119">M1402</td>
			<td class="xl21">Materials for poly-lipid hybrid nanoparticles</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">Polyoxyethylene (40) Stearate</td>
			<td class="xl20" style="width:122pt" width="162">Sigma-Aldrich</td>
			<td class="xl20" style="width:89pt" width="119">P3440</td>
			<td class="xl21">Materials for poly-lipid hybrid nanoparticles</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">Pluronic F68 (PF68)</td>
			<td class="xl20" style="width:122pt" width="162">BASF Corp.</td>
			<td class="xl20" style="width:89pt" width="119">9003-11-6</td>
			<td class="xl21">Materials for poly-lipid hybrid nanoparticles</td>
		</tr>
		<tr height="42" style="height:31.5pt">
			<td class="xl20" height="42" style="width:188pt;height:31.5pt" width="250">Ultrasonication (UP100H)</td>
			<td class="xl20" style="width:122pt" width="162">Hielscher, Ultrasound Technology</td>
			<td class="xl20" style="width:89pt" width="119">NA</td>
			<td class="xl21">Nanoparticle preparation</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">Water Bath (ISOTEMP 3016HS)</td>
			<td class="xl20" style="width:122pt" width="162">Fisher Scientific</td>
			<td class="xl20" style="width:89pt" width="119">NA</td>
			<td class="xl21">Nanoparticle preparation</td>
		</tr>
		<tr height="105" style="height:78.75pt">
			<td class="xl20" height="105" style="width:188pt;height:78.75pt" width="250">Liposomal Doxorubicin&#160; (Caelyx)</td>
			<td class="xl20" style="width:122pt" width="162">Janssen</td>
			<td class="xl20" style="width:89pt" width="119">Purchased from the pharmacy Princess Margaret Hospital</td>
			<td class="xl21">Clinically-approved nanoparticle formulation&#160;</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">HPLC-graded Methanol</td>
			<td class="xl21">Caledon Chemicals</td>
			<td class="xl20" style="width:89pt" width="119">6701-7-40</td>
			<td class="xl21">HPLC mobile phase composition</td>
		</tr>
		<tr height="25" style="height:18.75pt">
			<td class="xl20" height="25" style="width:188pt;height:18.75pt" width="250">HPLC-graded H2O</td>
			<td class="xl21">Caledon Chemicals</td>
			<td class="xl20" style="width:89pt" width="119">8801-7-40</td>
			<td class="xl21">HPLC mobile phase composition</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">HPLC-graded Acetonitrile&#160;</td>
			<td class="xl20" style="width:122pt" width="162">Caledon Chemicals</td>
			<td class="xl20" style="width:89pt" width="119">1401-7-40</td>
			<td class="xl21">HPLC mobile phase composition</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">Trifluoroacetic Acid</td>
			<td class="xl20" style="width:122pt" width="162">Sigma-Aldrich</td>
			<td class="xl20" style="width:89pt" width="119">302031</td>
			<td class="xl21">HPLC mobile phase composition</td>
		</tr>
		<tr height="42" style="height:31.5pt">
			<td class="xl20" height="42" style="width:188pt;height:31.5pt" width="250">0.45 &#956;m Nylon Membrane Filter Paper</td>
			<td class="xl20" style="width:122pt" width="162">Whatman</td>
			<td class="xl20" style="width:89pt" width="119">WHA7404004</td>
			<td class="xl21">HPLC mobile phase preparation</td>
		</tr>
		<tr height="42" style="height:31.5pt">
			<td class="xl29" height="42" style="height:31.5pt">1cc Plastic Syringes</td>
			<td class="xl20" style="width:122pt" width="162">Becton, Dickinson and Company</td>
			<td class="xl20" style="width:89pt" width="119">2606-309659</td>
			<td class="xl21">Treatment injection</td>
		</tr>
		<tr height="42" style="height:31.5pt">
			<td class="xl29" height="42" style="height:31.5pt">5cc Plastic Syringes</td>
			<td class="xl20" style="width:122pt" width="162">Becton, Dickinson and Company</td>
			<td class="xl20" style="width:89pt" width="119">2608-309646</td>
			<td class="xl21">Tissue collections</td>
		</tr>
		<tr height="42" style="height:31.5pt">
			<td class="xl20" height="42" style="width:188pt;height:31.5pt" width="250">30G 1/2 Needles</td>
			<td class="xl20" style="width:122pt" width="162">Becton, Dickinson and Company</td>
			<td class="xl20" style="width:89pt" width="119">305106</td>
			<td class="xl21">Treatment injection</td>
		</tr>
		<tr height="42" style="height:31.5pt">
			<td class="xl20" height="42" style="width:188pt;height:31.5pt" width="250">25G 5/8 Needles</td>
			<td class="xl20" style="width:122pt" width="162">Becton, Dickinson and Company</td>
			<td class="xl20" style="width:89pt" width="119">305122</td>
			<td class="xl21">Tissue collections</td>
		</tr>
		<tr height="42" style="height:31.5pt">
			<td class="xl20" height="42" style="width:188pt;height:31.5pt" width="250">Sterile 0.9% Saline</td>
			<td class="xl20" style="width:122pt" width="162">Univeristy of Toronto House Brand</td>
			<td class="xl20" style="width:89pt" width="119">1011</td>
			<td class="xl21">Tissue perfusion</td>
		</tr>
		<tr height="22" style="height:16.5pt">
			<td class="xl20" height="22" style="width:188pt;height:16.5pt" width="250">13 ml Rounded-bottom conical tube&#160;</td>
			<td class="xl20" style="width:122pt" width="162">SARSTEDT</td>
			<td class="xl20" style="width:89pt" width="119">62.515.006</td>
			<td class="xl21">Prolyprolene, tissue homogenization</td>
		</tr>
		<tr height="23" style="height:17.25pt">
			<td class="xl30" height="23" style="height:17.25pt">Alpha Minimum Essential Medium (MEM)&#160;</td>
			<td class="xl27">Gibco</td>
			<td class="xl28" style="width:89pt" width="119">12571063</td>
			<td class="xl21">Cell medium</td>
		</tr>
		<tr height="22" style="height:16.5pt">
			<td class="xl20" height="22" style="width:188pt;height:16.5pt" width="250">1 x Phosphate Buffer Saline</td>
			<td class="xl20" style="width:122pt" width="162">Gibco</td>
			<td class="xl20" style="width:89pt" width="119">10010023</td>
			<td class="xl21">Tissue homogenization</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">Triton X-100</td>
			<td class="xl20" style="width:122pt" width="162">Sigma-Aldrich</td>
			<td class="xl20" style="width:89pt" width="119">X100-100 ML</td>
			<td class="xl21">Tissue homogenization</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">Formic acid</td>
			<td class="xl20" style="width:122pt" width="162">Caledon Chemicals</td>
			<td class="xl20" style="width:89pt" width="119">1/5/3840</td>
			<td class="xl21">Adjust pH for extraction solvent</td>
		</tr>
		<tr height="42" style="height:31.5pt">
			<td class="xl20" height="42" style="width:188pt;height:31.5pt" width="250">Sodium heparin sprayed plastic tubes</td>
			<td class="xl20" style="width:122pt" width="162">Becton, Dickinson and Company</td>
			<td class="xl20" style="width:89pt" width="119">367878</td>
			<td class="xl21">Blood collection</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">Analytical Weigh Balance&#160;</td>
			<td class="xl20" style="width:122pt" width="162">Sartorius&#160;</td>
			<td class="xl21">CPA225D</td>
			<td class="xl21">NA</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">pH meters&#160;</td>
			<td class="xl20" style="width:122pt" width="162">Fisher Scientific</td>
			<td class="xl26">13-637-671</td>
			<td class="xl21">accumet BASIC</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">Vortex Mixter</td>
			<td class="xl20" style="width:122pt" width="162">Fisher Scientific</td>
			<td class="xl20" style="width:89pt" width="119">02-215-365</td>
			<td class="xl21">Vortexing samples at desired speed</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">1.5 ml&#160; Microcentrifuge Tube</td>
			<td class="xl20" style="width:122pt" width="162">Fisherbrand</td>
			<td class="xl20" style="width:89pt" width="119">2043-05408129</td>
			<td class="xl21">Prolyprolene</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">Model 1000 homogenizer</td>
			<td class="xl22">Fisher Scientific</td>
			<td class="xl20" style="width:89pt" width="119">08-451-672</td>
			<td class="xl21">Tissue homogenization</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">Centrifuge 5702R</td>
			<td class="xl20" style="width:122pt" width="162">Eppendorf</td>
			<td class="xl20" style="width:89pt" width="119">5702R</td>
			<td class="xl21">Extraction preparation</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">Heated Evaporator System</td>
			<td class="xl20" style="width:122pt" width="162">Glas-Col</td>
			<td class="xl20" style="width:89pt" width="119">NA</td>
			<td class="xl21">Sample reconstitution</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">HPLC Screw Thread Vials</td>
			<td class="xl20" style="width:122pt" width="162">DIKMA</td>
			<td class="xl20" style="width:89pt" width="119">5320</td>
			<td class="xl21">HPLC sample injection</td>
		</tr>
		<tr height="42" style="height:31.5pt">
			<td class="xl20" height="42" style="width:188pt;height:31.5pt" width="250">HPLC Screw Caps with PTFE White Silicone Septa</td>
			<td class="xl20" style="width:122pt" width="162">DIKMA</td>
			<td class="xl20" style="width:89pt" width="119">5325</td>
			<td class="xl21">HPLC sample injection</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">HPLC Polypropylene Insert&#160;&#160;</td>
			<td class="xl20" style="width:122pt" width="162">Agilent Technologies</td>
			<td class="xl20" style="width:89pt" width="119">5182-0549</td>
			<td class="xl21">Maximum volume 250 &#956;l, HPLC sample injection</td>
		</tr>
		<tr height="25" style="height:18.75pt">
			<td class="xl20" height="25" style="width:188pt;height:18.75pt" width="250">Xbridge C18 Column</td>
			<td class="xl23">Waters Corporation</td>
			<td class="xl20" style="width:89pt" width="119">186003117</td>
			<td class="xl21">Drug analysis</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">Gradient pump&#160;</td>
			<td class="xl23">Waters Corporation</td>
			<td class="xl20" style="width:89pt" width="119">W600</td>
			<td class="xl21">Drug analysis</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">Auto-sampler</td>
			<td class="xl23">Waters Corporation</td>
			<td class="xl20" style="width:89pt" width="119">W2707</td>
			<td class="xl21">Drug analysis</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">Photodiode array detector&#160;</td>
			<td class="xl23">Waters Corporation</td>
			<td class="xl20" style="width:89pt" width="119">W2998</td>
			<td class="xl21">Drug analysis</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">Multi &#955; fluoresence detector&#160;</td>
			<td class="xl23">Waters Corporation</td>
			<td class="xl20" style="width:89pt" width="119">W2475</td>
			<td class="xl21">Drug analysis</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">EMPOWER 2</td>
			<td class="xl23">Waters Corporation</td>
			<td class="xl20" style="width:89pt" width="119">NA</td>
			<td class="xl21">Data analysis software</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">Scientist</td>
			<td class="xl20" style="width:122pt" width="162">Micromath</td>
			<td class="xl20" style="width:89pt" width="119">NA</td>
			<td class="xl21">Pharmacokinetic analysis</td>
		</tr>
		<tr height="21" style="height:15.75pt">
			<td class="xl20" height="21" style="width:188pt;height:15.75pt" width="250">Female Balb/c Mice</td>
			<td class="xl20" style="width:122pt" width="162">Jackson Laboratory</td>
			<td class="xl20" style="width:89pt" width="119">001026</td>
			<td class="xl21">In vivo</td>
		</tr>
		<tr height="63" style="height:47.25pt">
			<td class="xl20" height="63" style="width:188pt;height:47.25pt" width="250">EMT6/WT Breast Cancer Cells</td>
			<td class="xl20" style="width:122pt" width="162">Provided by Dr. Ian Tannock; Ontario Cancer Institute</td>
			<td class="xl20" style="width:89pt" width="119">NA</td>
			<td class="xl21">In vivo</td>
		</tr>
	</tbody>
</table>

sample extraction and simultaneous chromatographic quantitation of doxorubicin and mitomycin c following drug combination delivery in nanoparticles to tumor-bearing mice

Kombination kemoterapi er ofte bruges i klinikken til behandling af cancer; tilknyttede bivirkninger til normale væv kan dog begrænse sit terapeutiske fordel. Nanopartikler-baseret drug kombination har vist sig at mindske problemer med fri narkotika kombinationsbehandling. Vores tidligere undersøgelser har vist, at kombinationen af to anticancermedicin, doxorubicin (DOX) og mitomycin C (MMC), produceret en synergistisk effekt mod begge murine og human brystkræft celler i vitro. DOX og MMC Co indlæst polymer-lipid hybrid nanopartikler (DMPLN) omgås forskellige efflux transporter pumper, der giver multidrug resistance og demonstreret forbedret effektivitet i bryst tumor modeller. Sammenlignet med konventionelle løsning former, blev sådan superior effekten af DMPLN tilskrevet den synkroniserede farmakokinetik DOX og MMC og øget intracellulær stof biotilgængelighed inden for tumorceller aktiveres med nanocarrier PLN.
For at evaluere farmakokinetik og bio-distribution af administreres Co DOX og MMC i både gratis løsning og nanopartikel former, en enkel og effektiv multi drug analysemetoden med omvendt fase højtydende væskekromatografi (HPLC) var udviklet. I modsætning til tidligere rapporteret metoder, der analyseres DOX eller MMC individuelt i plasma, er denne nye HPLC-metoden i stand til samtidigt kvantificere DOX, MMC og en større cardio-giftige DOX metabolit, doxorubicinol (DOXol), i forskellige biologiske matricer ( fx fuldblod, bryst tumor og hjertet). En dobbelt fluorescerende og ultraviolet absorberende sonde 4-methylumbelliferone (4-MU) blev brugt som en intern standard (I.S.) for et-trins påvisning af flere retskemisk med registrering af forskellige bølgelængder. Denne metode blev anvendt til at bestemme koncentrationen af DOX og MMC leveret af både nanopartikel og løsning tilgange i fuldblod og forskellige væv i en orthotopic bryst tumor murine model. Den analytiske metode præsenteret er et nyttigt værktøj til præ-klinisk analyse af nanopartikler-baserede levering af narkotika kombinationer.

To anticancermedicin, DOX og MMC samt DOX metabolit, DOXol, blev samtidig registreret uden biologiske indblanding under den samme anvendt gradient HPLC tilstand ved hjælp af 4-MU som I.S. for både fluorescens og UV detektorer. DOX, MMC, DOXol og 4-MU var godt adskilt fra hinanden med retentionstider af 5,7 min til MMC, 10.4 min til DOXol, 10,9 min for 4-MU og 11,1 min for DOX (figur 2). Hver enkelt drug i fuldblod og forskellige væv viste koncentration lin...

Watch this Scientific Journal Video about Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-b

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Prøven udvinding og samtidige kromatografiske kvantitering af Doxorubicin og Mitomycin C efter narkotika kombination levering i nanopartikler til Tumor-bærende mus

Denne protokol beskriver et effektivt og praktisk analytisk proces af prøven udvinding og samtidige bestemmelse af flere stoffer, doxorubicin (DOX), mitomycin C (MMC) og en cardio-giftige DOX metabolit, doxorubicinol (DOXol), i biologiske prøver fra en prækliniske bryst tumor model behandlet med nanopartikel formuleringer af synergistiske drug kombination.

Combination chemotherapy is frequently used in the clinic for cancer treatment; however, associated adverse effects to normal tissue may limit its ...

Research

JoVE Journal

Cancer Research

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Brug RNA-sekventering til Detect Novel Splice Varianter Relateret til Drug Resistance i<em&gt; In vitro</em&gt; Kræft Modeller

Drug resistance remains a major problem in the treatment of cancer for both hematological malignancies and solid tumors. Intrinsic or acquired resistance ...

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Den Colon-26 Carcinoma Tumor-bærende mus som en model for Studiet af Cancer Kakeksi

Cancer cachexia is the progressive loss of skeletal muscle mass and adipose tissue, negative nitrogen balance, anorexia, fatigue, inflammation, and ...

In Vivo EPR Assessment of pH, pO2, Redox Status, and Concentrations of Phosphate and Glutathione in the Tumor Microenvironment

In Vivo EPR Assessment of pH, pO2, Redox Status, and Concentrations of Phosphate and Glutathione in the Tumor Microenvironment

In Vivo EPR vurdering af pH, pO2, Redox Status, og koncentrationen af fosfat og glutathion i Tumor mikromiljø

This protocol demonstrates the capability of low-field electron paramagnetic resonance (EPR)-based techniques in combination with functional paramagnetic ...

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Metoder til evaluering af c-Fos rolle og Dusp1 i onkogen afhængighed

The demonstration of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML) has heralded a new era in cancer therapeutics. However, ...

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potensering af Anticancer antistof effektivitet af antineoplastiske stoffer: påvisning af antistof-drug synergi med kombination indeks ligning

Potentiation of hostile monoclonal antibodies (mAb) by chemotherapeutic agents constitutes a valuable strategy for designing effective and safer therapy ...

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Overførsel af manipulerede tumor-associerede neutrofiler til tumor bærende mus for at studere deres angiogene potentiale in vivo

The contribution of neutrophils to the regulation of tumorigenesis is getting increased attention. These cells are heterogeneous, and depending on the ...

In Vivo Imaging and Quantitation of the Host Angiogenic Response in Zebrafish Tumor Xenografts

In vivo billeddannelse og Kvantitation af værten Angiogen respons i Zebrafish tumor Xenografts

Tumor angiogenesis is a key target of anti-cancer therapy and this method has been developed to provide a new model to study this process in vivo. A ...

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1&#945; Nanoparticles

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1ÃƒÅ½Ã‚Â± Nanoparticles

Evaluering af in vivo antitumoraktivitet af polyanhydrid IL-1α nanopartikler

Cytokine therapy is a promising immunotherapeutic strategy that can produce robust antitumor immune responses in cancer patients. The proinflammatory ...

Exploring Mitochondrial Energy Metabolism of Single 3D Microtissue Spheroids Using Extracellular Flux Analysis

Udforskning af mitokondrieenergimetabolisme af enkelt 3D-mikrotissu-sfroider ved hjælp af ekstracellulær fluxanalyse

Three-dimensional (3D) cellular aggregates, termed spheroids, have become the forefront of in vitro cell culture in recent years. In contrast to culturing ...

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Samtidig billeddannelse og flowcytometribaseret påvisning af flere fluorescerende ældningsmarkører i terapiinducerede senescente kræftceller

Chemotherapeutic drugs can induce irreparable DNA damage in cancer cells, leading to apoptosis or premature senescence. Unlike apoptotic cell death, ...